# Eli Lilly Posts Higher Revenue on Continued GLP-1 Demand

> **Open Intelligence Dossier** · First detected: 2026-08-05 18:07 UTC · Category: Business

## Executive Summary
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"Eli Lilly Posts Higher Revenue on Continued GLP-1 Demand" is generating significant coverage in the Business category, with 4 articles from 4 distinct sources tracked by PULSE so far.


Outlets currently covering the story include Yahoo Finance, Pharmaceutical Technology, USA Today and Forbes. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Yahoo Finance | Eli Lilly stock soars on strong demand for weight-loss drugs | [Source Link](https://news.google.com/rss/articles/CBMiwgFBVV95cUxPOFlETUJidnVsdkxvSHd1SUpIRWVxVXdVbFFVdWFtallxWE1rdno3eFg4MFIxVW1ibGVyWmNMb2VNR0poLUIzTTgybzl2ZC1pOVRza0ZOTUJwbEJlbDBqQW5pcktqXzZ1NmVmcWVibGNneEEzaENBT005QS1PN3RHTVJmN0d3TDJZc2Rod09sM0pxOGNvTmpQZUItdzh0clc5VGpRVVpzV1RKM2tKTmtQTXROT2M0dWh4eHY1QXlhck9VUQ?oc=5) |
| Pharmaceutical Technology | Eli Lilly raises 2026 outlook again as Q2 soars past estimates | [Source Link](https://news.google.com/rss/articles/CBMirwFBVV95cUxQUGYtbWlOWjE2VUt4b0MtQTZrUkZTTGo3Q3BXdndhT0Y4cXdaaVlkYXFkU0tIcklVS3hrbDRLMU52SE1wU3lBWUtiX2trUWJQRVgxajNUbEpEeVgtRHJjNjJMUG1YMTBad0U5QWxSOUJJMDk5RWY2b3JUaXAxWm5DUTQxZXBjYkhaWG52eXFGcnpZRXYwVGl3ZGplcU5SZkFHOHJXcHQyc0ZScVlEeTNr?oc=5) |
| USA Today | Eli Lilly widens obesity drug lead as Zepbound, Mounjaro sales soar | [Source Link](https://news.google.com/rss/articles/CBMinAFBVV95cUxPOEhWU3A5cml2V1AxLW1ISWNiMDAtZ0NPYVB3NVNxd19pbTJsYkpkMl82RFg4QnBXTEZ2MmUxbjFwMU5uQVBUSkJnQ0VkbjdhZW5XeHlxUGwweThmdzVNeU5aMlg5b0NFak1XcWpnTEFpLWtmbDNXRnFGdnRUV1M0LVBoaFRVVm9jcUxxUWw2SHNIdHlYaGRyZVh6T24?oc=5) |
| Forbes | Eli Lilly’s Obesity Drugs Drive Massive Revenue Growth | [Source Link](https://news.google.com/rss/articles/CBMiqwFBVV95cUxPdjMxWFgtNzF2Wi1obXBEUXlOMDBpQk9kbFdpQmIyS2dFVHg0S3FXWklTS1l6VkRBWDczTjM5MC1Hb2x6Q2tHb0RlOGJEVG16RmVXU0E1djU0WHVXRHMyN25QXzBjNGxubURJdmV5RTFHdFpqMlRscDcxenhrU2NlRlNBQ0lEYVd5VHFvNnJwRU83OVo4NFd4ZkdzZVBycFBNX3N6UW1pV0RIZmc?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-08-05/eli-lilly-posts-higher-revenue-on-continued-glp-1-demand*